Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study
Crossref DOI link: https://doi.org/10.1186/s13075-016-0995-0
Published Online: 2016-04-22
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Han, Bobby Kwanghoon
Kuzin, Igor
Gaughan, John P.
Olsen, Nancy J.
Bottaro, Andrea
Funding for this research was provided by:
Cooper Foundation
